Ashland Inc. (NYSE:ASH)
Bands
Volume
200 SMA
50 SMA
20 SMA
Videos
Alerts
Articles
Events
Old Forum Content for ASH
Make a Forum Post Become a member to view recent forum posts. Already a member? Sign in here.
- wineinquirer: $ASH Very strong move this am on hvy vol. Posted about this yesterday and has been also featured in IBD recently. Powered through bo this am. Picked some up @108. will add on pb bounce
- wineinquirer: $ASH multi-mo inv h&s with handle that has a nearly complete smaller inv h&s. Chemicals strong IBD industry (31/197). Could take a small entry on flag bo >108 and add if multi mo bo >111. tgt 1 125 (16%), then 135 (25%). As @brobert proclaims.......watch & react!
- Pokersmith: @issues $KRO $CC $VHI $ASH see also : $LIN
- issues: Comparing chemicals specialty group: $KRO $CC $VHI $ASH. I like CC and VHI then ASH. I hope my position doesn't turn to ash... which one to buy? I don't like to buy at the high, so I put in a limit order at $39.95 on CC. I am buying the ones that pulled back a little $VHI & $ASH.
- Pokersmith: @issues $KRO $CC $VHI $ASH $LIN Thanks...will give your picks a once over 👍
- Pokersmith: @Pokersmith $KRO $CC $VHI $ASH $LIN Same industry, but different sub-industries. No small concern when making comparisons
- issues: @Pokersmith $KRO $CC $VHI $ASH $LIN Yes Lin looks good also. The IBD accumulation rating for LIN is C+ but ASH is B, and VHI is A. The IBD #1 pick is VHI and it's #1 on Relative strength. With the price of LIN I could buy both ASH and VHI. Now watch LIN shoot up without me, eh? Also on the ten day chart LIN is up 8% and ASH is also up 8%, but VHI is 14%! The trend is your friend. I'm going to put in a limit order for LIN because of slightly declining volume and it is at the top...I hate to buy at the very tippy top. Limit order on LIN $305 in place. Look at how it dropped last time it hit this high. From $333 to $297. If the market drops I might get lucky, right?
- Pokersmith: @issues $KRO $CC $VHI $ASH $LIN #1 #1 no doubt, but if it DOES go there ( 305 ) would you really want to own it? . It essentially would have proven that it has lost momentum and this potential short /intermediate term break out is for naught.
- issues: @Pokersmith $KRO $CC $VHI $ASH $LIN Right. I also hold $WLK in IBD group 36 (Chemicals) but it's down 2% in 10 days while the others, VHI ASH LIN are in IBD group 48 - obviously not as good a group - but they are up much more!
- Pokersmith: @issues $KRO $CC $VHI $ASH $LIN #1 #1 50 week sma is at 312...support roughly at 308
- woodman: @issues $KRO $CC $VHI $ASH - Look also $GPRE's action today - continuation of move higher after closing above the 200d yesterday.
- mogo: $ASH looks like phase 3 today
- mogo: $ASH breaking out of tight squeeze
- Hemal: $ASH squeezing- this may offer a good risk/reward scenario for a trade h... https://youtu.be/8YpByybkZo4 via @YouTube
- Bob G: @Mitchell $AAL $AMT $ASH $CBOE $FFIV $JBLU $LOW $LYFT $PAYC $PCTY $WHR Great update and really appreciated!
- Trudy Warren: @Mitchell $AAL $AMT $ASH $CBOE $FFIV $JBLU $LOW $LYFT $PAYC $PCTY $WHR Thank you for sharing your trading notes!
-
Mitchell: ...
$ASH - dropped nearly 9% on the week, but shares remain in the $70-$80 range since the start of the year. Shares go ex-dividend on 11/29 ($0.275 per share).
$CBOE - breakout on the weekly chart above the $122.50 level. The next major resistance lev ... -
Ajax4Hire: ...
$ABT $ABUS $ACIA $ADRO $AEM $AFL $AGCO $AGX $AIG $ALGN $ALKS $ALL $AMP $AMT $ANAB $ANF $ANTM $AOBC $APA $APT $APYX $ASH $ASIX $AYI $BAX $BCRX $BEAT $BIDU $BIIB $BKD $BKNG $BLMN $BLOK $BMY $BOOM $CACC $CALA $CARS $CCI $CDE $CELG $CENT $CGEN $CHK $CLV ... - Aragorn: @Ajax4Hire $ABT $ABUS $ACIA $ADRO $AEM $AFL $AGCO $AGX $AIG $ALGN $ALKS $ALL $AMP $AMT $ANAB $ANF $ANTM $AOBC $APA $APT $APYX $ASH $ASIX $AYI $BAX $BCRX $BEAT $BIDU $BIIB $BKD $BKNG $BLMN $BLOK $BMY $BOOM $CACC $CALA $CARS $CCI $CDE $CELG $CENT $CGEN ...
-
Mitchell: ...
$ASH - gapped higher to retest the $80 resistance level, but ended lower on the session
$CMG - up 6 consecutive days, confirming a new closing and intra-day high. Watch for a pullback closer to $700 for a lower risk entry; for existing bullish posi ... -
Mitchell: ...
$ASH - I mentioned this one yesterday. Shares gapped lower and continued to drop throughout the day. Look for a retest of the low $70's in the near-term.
BIDU- The stock is down 32% this month after the weak earnings outlook and it hasn't started t ... -
Mitchell: ...
$ASH - shares broke down earlier this month and are now testing prior support at the $76-$77 level (also the 100-day SMA). If we start to see sellers step back in, consider a bearish position with a stop loss above $77.
$BKNG - down 4 days in a row ... - ricsnyde: Specialty Chems basing and some moving up: $POL $ASH
- bRobert: @ricsnyde $POL $ASH Many perky names in the group. $alb .$sqm $fmc setting up.
- ab3250: $ASH - short?
- Junior1: @ab3250 $ASH I've been doing well shorting the morning gap ups. But this is not a good candidate, as it's moved up on good volume all morning. but if you do short this, use intraday high as your exit
- Aragorn: A few stocks keying on for day trades tomorrow - Inside days - $PANW $LH $UNH $TNA $ CASy - $ASH $LGND $CME - pullback t he 21ema inside day $RL $NFLX $CCI $ANET $EBIX $UAL $WDVC Hammer signals OPHT - also an inside day - $HDS $CREE
- orpheusredux: @Aragorn $PANW $LH $UNH $TNA $ASH $LGND $CME $RL $NFLX $CCI $ANET $EBIX $UAL $WDVC $HDS $CREE Ara--as I posted yesterday, I believe $OPHT looks very buyable here.
- JJT1: $ASH $RPM $CLX $DOW $WDFC $WDFC continues vs breakout from couple days ago. Others all in approx 3 % VS in kinda winners circle...while I am waiting on $DD or $MEOH.
- bwcarnation1: $ASH above recent hi b.o. from tight sq. long i.h.s. going back to november
- woodman: #Chemicals stocks that are working well (as distinguished from the also nicely-performing #SpecialtyChemicals stocks I've provided in the recent and more distant past): $TROX $RYAM $SQM $HUN $FMC $EMN $AXLL $APD $MTX $UNVR $ASH $DOW (FD - of these, I am long only TROX.)
-
Paddleboard: ...
$AAPL $ABUS $ACAD $ADRO $ADXS $AEGR $AEM $AIG $ALE $AMBA $APC $APOL $ASH $AU $BDSI $BG $BHI $BHL $BIN $BITI $BMY $BRCD $BYD $CASY $CAT $CBRL $CL $CLF $CLNE $CMI $CNP $CNQ $COG $COP $CORE $CRM $CRUS $CSCO $DANG $DDD $DJ-30 $DLTR $DO $DPLO $EBIX $EBS ... - woodman: #Chemical Stocks: I mentioned $MON below. Might be able to get it a little lower on a pullback to 8dEMA or maybe even the 50 day. The 200 day is ~ $15 higher. Some others: $FMC (also maybe on a pullback to the 50 day or prior resistance ~ $31.18), $AXLL (flirting with move above the 50 day); $ASH (on move above $110.59), $HUN (on move above $13.48/50 day), $RYAM (if this turns out to be a successful hold/test of yesterday's gap up = $8.97).
-
snakedriver: ...
when I got back active after my chemo, the 1st thing I did was search for “Henry's list". I never did find it (new forum format I guess); anyway, a search for @Henry turned up a post by Aragorn – sorry, I didn't save the date & ... - ginny: $ASH for anyone who follows the TTM squeeze on TOS this is showing a weekly and daily squeeze.
-
TRICIA: ...
I can't believe it is Nov --#ASH2014 is only 5 wks away. I will be confirming updates and will post this week.
his is from Leerink last spring
PI/II CDX-1127 data for solid tumor cohort expected at ASCO 2014 while $ASH 2014 would be data releas ... -
DAN: $TWTR -- bullish today
The indexes are reversing today, giving us a tradable bounce. Here are some stocks that are standing out:
$LEA -- definite bottom on 200-day MA
$CSX -- buyable bounce.
$DECK -- today's intraday low is THE low
$FB -- bounce is ... - janner0814: DAN... Superb video... covered so much in 8 minutes? Compelling message on Chemicals, Auto, QIHU and Energy: Loud & Clear... not right now... $DOW $ASH $MOS $MDR $QIHU $LEA $BWA $F $GM $PBY $HAL $XLE $XOP $OIH $COP $BHI $NBR $SLB
- NapoleonSolo: $ASH one to consider for a trade ...done going down IMO ... long stock or bull put spread at/ below recent low of 98 and change looks like stand-up support
- Neil375: $AGU Agrium Looks like it's trying to put in a bottom. Stochasics crossing in oversold. Bullish candle on Friday and a Doji froming today. Just below the 200 and looks like a low risk entry. Some of the chemical companies are also looking bullish today. $MON, $LYB,$ASH and$WLK.
- Neil375: $ASH - Ashland - Good morning. The last few days I've been remiss in checking my scans. So, I'm late to the party. However these chemical company stocks are working. A couple more - $WLK, $LYB and $CLMT.
-
Aragorn: ...
$BIDU AAPL $USU XLF $WFC BAC $WYNN LVS $ASH
How to Game the Opening Rotation - November 28, 2007
http://www.stockmarketmentor.com/public/712.cfm
@Golf77's 7-10 day theory
http://www.stockmarketmentor.com/members/forum/openthread.cfm?forum=3& ... -
Tricia: ...
PI/II CDX-1127 data for solid tumor cohort expected at ASCO 2014 while $ASH 2014 would be data release for hematology cohort. Regarding potential PD1 collaboration ( $BMY , $MRK , ROCHE etc) they will expand on this MARCH 3rd the Earnings CC. # ... -
Tricia: ...
PI/II CDX-1127 data for solid tumor cohort expected at ASCO 2014 while $ASH 2014 would be data release for hematology cohort. Regarding potential PD1 collaboration ( $BMY , $MRK , ROCHE etc) they will expand on this MARCH 3rd the Earnings CC. # ... -
Tricia: ...
PI/II CDX-1127 data for solid tumor cohort expected at ASCO 2014 while $ASH 2014 would be data release for hematology cohort. Regarding potential PD1 collaboration ( $BMY , $MRK , ROCHE etc) they will expand on this MARCH 3rd the Earnings CC. # ... - Tricia: ARIA: @ Money HoHo .. Iclusig sales restarted just this week - as a result of the FDA reversal which the Oncologists who were present at $ASH 2013 in early December, made happen! .... this move is based on rumors but in 90 days it will be affected by new Scrips and Pimverserin .. long and holding ... my expectation is this will get back to 15 - 16 pps - more if there is a buyout
- Tricia: ARIA: @meched49 - don't be so hard on yourself .... I have followed $ARIA very closely - and got hit in early October when the FDA pulled Iclusig and it dropped from 20 to 2.75$ in less than 2 hours (had stops but the core holding was killed ). The first week of December at $ASH, a group of Oncologists ganged up on the FDA because there is nothing else to replace it and a few weeks earlier Iclusig had a positive CHMP. The FDA had to capitulate and they did. if $ARIA does what I expect, there is at least another $6 to $9 from here , regardless of a buyout ... take a small position and average up with every 1%. and be proud of yourself for trying to learn this this crazy world of trading!
-
Tricia: ...
Today $GILD is nearly the size of MERCK with a dominance in Infectious disease treatments that those other 6 dreamed of. In addition, ASCO and of course $ASH revealed just how focused, driven and effiecient the Mgmt team is ... they have success in ... - docschwaz: @Jorma: While limited data is available on this trial, the improvement in $PFS and OS should seal the deal as far as approval in CLL/SLL (SLL is the lymph node version of CLL; CLL is essentially SLL in the blood). Arzerra is already approved for 3 ...
- Tricia: ARIA: I posted this in yesterday's ....but I meant it for today......ARIA: I have posted many times on Ariad, I expect this stock to move toward it's high from last year..... a script watch will be helpful. The FDA capitulated on their decision after Europe approved the drug. The timing with $ASH allowed the Oncologists to meet and organize and they did a good job. The FDA decision was a good one . Will it be $22 or$18 .....can't tell you - we will have to watch the script counts..... But I am glad some of you jumped on this a few weeks ago!
- Tricia: ABBV: AbbVie's experimental breast cancer drug shows promise in study This co is not so much about $HEP C ... it is a big hit from $ASH and SABCS which wraps up today ... AbbVie's (ABBV +0.3%) experimental breast cancer veliparib proved especially promising against triple negative breast cancer, an aggressive form of the disease for which there are few effective treatments, according to results presented at a major symposium.Veliparib, when combined with the drug carboplatin and a six-month regimen of standard chemotherapy, achieved a complete response in 52% of patients vs. 26% for patients treated with standard chemo alone; late-stage cancer drug studies typically succeed only 30%-40% of the time.
- BuffaloBill: $CLF @jpbel2003 Excellent maybe, I use a Wilder RSI 14 for short term trend and its falling, but whos not to say $23.38 is going to be the lowest low of the year, and the Best Buy of the Year. Here's some charts that are in the winners circle in no particular order $OI ADS $CSX GT $ASH EVR $RCMT WAGE AKS.
- Tricia: BIOTECH - Fun DAy : $CYTR up 55% in 2 days - booked profits left with place holder $ZIOP up 6% in 2 days - holding IDRA: up 23.4% in 3 days ... back to place holder $GALE : stopped out Tuesday - bought back yesterday added a bit more today ... now 1/3 position RMTI: back in yesterday after being stopped out in 3 trances .... now 1/2 position .. with tight stop I followed $ASH before and the after effects all week .. based on conversations with Oncs , I shorted $IMUC @ $3.02,and shorted $NWBO @4.36 on Friday and shorted more Monday @4.66. Profit on $IMUC SHORT, closed it at $1.16 150%. Profit on $NWBO short - so far 25.67% on a full position .. may close before $EOD ... Homework and research pays off ...
-
Tricia: ...
$ABBV, $ENTA pre- $ASH buys - yea am happy. $GILD ... not worried about it at all ... Sofasbuvir outperforms $ALL the rising competition ( this is the liver guys opinions not mine) ... and when it is one pill, and only 6-8 weeks of treatment ... i ... -
Esslinger: ...
Celldex's CDX-301 in Combination with Mozobil(R) Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies; Results Presented at $ASH 2013
@HAMPTON, N.J., Dec. 10, 2013 (GLOB ... - Tricia: $ARIA up 6% .... the news is "old" in that Europe did not agree with US ..... and as I described in multiple posts since then, ICLUSIG is needed ... and the Oncs at $ASH and elswehere weighed in saying that the benefits exceeded the risks .... this move is expected - any FDA change of heart will be much further out ... hope it helps Twitter has some excellent credible Oncs that you can all follow ... you will get information before it appears in msg boards .... $ARIA. Iclusig to return "in time": Summer Street Summer Street is out with some commentary on Ariad Pharmaceuticals (ARIA +6.3%).Analyst Carol Werther says the company "appears to have the support of its clinicians regarding" Iclusig's safety.While Werther sees a "larger challenge" in working with the FDA on label changes, she says the drug "provides a clear unmet need and will return in time."
- Tricia: CLDX@ Mr. Adams ...Celldex's CDX-301 in Combination with Mozobil(R) Increases Hematopoietic Stem Cell Mobilization and Results in Improved Transplantation of Mobilized Cells in Preclinical Studies;(note preclinical studies) Results Presented at $ASH 2013 Tue, 10 Dec 2013 13:30:00 $GMT
- Tricia: $GENE THERAPY BIG WIN at $ASH 2013 : http://www.usatoday.com/story/news/nation/2013/12/07/gene-therapy-scores-big-wins-against-blood-cancers/3902431/ The treatment involves filtering patients' blood to remove millions of white blood cells called T-cells, altering them in the lab to contain a gene that targets cancer, and returning them to the patient in infusions over three days. Several drug and biotech companies are developing these therapies. Penn has patented its method and licensed it to Switzerland-based Novartis AG. The company is building a research center on the Penn campus in Philadelphia and plans a clinical trial next year that could lead to federal approval of the treatment as soon as 2016. PENN/NOVARTIS have treated the most ....24/27 pts are in complete remission ...
- Tricia: RHHBY: Today 10AM ET CC RHHBY's hematology franchise, incl. new clinical data and results presented during #ASH13 866 291 4166 also MabTheraSC & halo results of the head to head Gazyva (obinutuzumab) vs Rituxan study in the plenary session this afternoon. ONCs saying the dat is so amazing they would start using tomorrow ... Delivers another blow to $PCYC .... "The fact that treatment was so short (6 months), the survival improvement is excellent, oh, and the cost seems reasonable." The monthly cost of Imbruvica ($10,900 in MCL, likely a bit less in CLL) seems to have surprised a few people here given the drug is given until progression and patients are still on it after 2-2.5 years so far. Note that the treatment cost (over 6 months) for Gazyva is only $41.3K, which is a lot less in comparison. This was approved last month - but data was held for $ASH ... E
- Tricia: $ASH 2013 .... large cap companies were presenting for last 2 days - today will more mid and small cap .... look for announcments all day ..... $GILD, RHHBY, $ABBV, $NVS maybe $INFI, and fade for PCYC..... there are some others to watch -- $ARRY, $ARIA, $BLUE, $GERN ........ the clear winner on all fronts is GILEAD ...... just incredible .... so it RHHBY ... and then there is $NVS and $CART T cell tx ... so far real hope for children, families, long suffering patients with heretofore death sentences ..... I wish I was at $ASH, - I am looking forward to todays news !
- Tricia: PCYC: If you read about $GILD and others at $ASH ... $PCYC is clearly wounded ... mgt stalled and wasted time .... now it is down - and if RHHBY goes forward and all signs are it will : Roche reports "unprecedented" results in CLL study Roche (RHHBY -0.8%) says Phase 3 data from a study of GA101 in CLL show patients "experienced nearly a year of extra remission time when treated with GA101 in combination with chlorambucil, compared with MabThera and chlorambucil."Median PFS: 26.7 months versus 15.2 months; HR=0.39.CR rate: 21% for GA101/chlorambucil versus 7% for MabThera/chlorambucil.The company calls the results "unprecedented": "For the first time in a first-line Phase 3 CLL study, we have seen a therapy that shows superior efficacy over MabThera," Roche says $PCYC going to the ICU.....
- scottto: $GILD - @Tricia - Well an excellent $ASH for GILD! As expected. Typically all of our good news lately has led to a selling day - meaning the good news is baked in. Perhaps these CLL data are impressive enough to surprise even the "unsurpriseable". ...
-
Tricia: ...
From SA: Technology now licensed to Novartis (NVS) for clinical testing is showing promise in the treatment of blood cancer, studies outlined at $ASH show.Chimeric antigen receptors, or CARs, are T-cells that have been modified to target leukemia c ... - Tricia: INFI: Infinity Pharmaceuticals reports data from IPI-145 blood cancer studies (PHASE 1 studies) .....getting mixed reviews ... I think it may be too soon to jusge Infinity Pharmaceuticals (INFI) reports preclinical data that demonstrates the activity of IPI-145 (PI3K inhibitor) in models of DLBCL and T-ALL.INFI also says Phase 1 data in aNHL shows the treatment "led to a reduction in adenopathy" in three of eight DLBCL patients and two of three with Richter transformation. (PR)in other company news from $ASH, $INFI says updated Phase 1 data from an ongoing study in relapsed/refractory indolent iNHL shows IPI-145 is clinically active "with an overall response rate of 73%." There were 3 CRLs and 53% of patients "remained progression free for over one year." (PR)Finally, $INFI says IPI-145 "was highly active in patients with relapsed/refractory CLL." Nodal response rate: 89%. OR rate: 48%.
- Tricia: CELG: First Analysis of Extended Dosing with Celgene Epigenetic Agent CC-486 in Patients with Higher-Risk Myelodysplastic Syndromes Presented at $ASH http://finance.yahoo.com/news/first-analysis-extended-dosing-celgene-023700507.html
- Tricia: GILD: a star at $ASH ... also $ABBV ..... PCYC/JNJ not going to see the revenue they once thought! Good article for you r Sunday ...http://www.bloomberg.com/news/2013-12-05...
- Trixie: $ASH looks to be breaking out.. Hope who ever was asking about it is along for the ride.
- Tricia: ABBV: $ASH affect alert - joint venture with another $ASH co, RHHBY( Roche) ABT-199 or GCS-0199 .. a bcl-2 inhibitor - enrolling a large phase II group - the larger trial will allow them to file for $AA ( accelerated approval ) if the data holds up .... Phase II study is for refractory/relapsed CLL. Other studies include ABT-199 +Rituxan versus Rituxin and Chemo. ALso haev a study startin with Roche again, for CD-20 mab; - in all blood cancers $MM, MCL, DLBCL and CLL ... with a powerhouse ... smart move by $ABBV and Roche Expect significant updates this weekend .. and I have a $PT of $56. It is above the upper BB right now, so you may want to gab 10 shares and watch ... g/l I also hold 1/4 p ROCHE since ASCO
- debeers: $ASH vs PPG-What you care about is total return and good value. That is how a stock should be judged. I leave price points to @DAN. You don't care how much a stock is, if it is expensive for you--buy less. What you care about is how great the per cen ...
- Esslinger: CGIX: presenting at $ASH, anyone still long this one? It looks to be at a buy point. Cancer Genetics, Inc. (Nasdaq:CGIX), an emerging leader in DNA-based diagnostics, is presenting data from its research collaboration with Memorial Sloan-Kettering Ca ...
- Tricia: IS ANYBODY $ELSE EXHAUSTED $FORM THIS WEEK ????? Up , Down, repeat !Up , Down, repeat !Up , Down, repeat ! I am off to the gym. I am leading some ski trips with the first one just 4 weeks away ..OMG!!! I have been on a 30 day diet and so far, I have lost 30 days ....... sheesh Have a great weekend & may $ASH bring good news to those who have been waiting! Monday watch for newsworthy results in $ABBV, $BIIB, $CLDX, GELG,CRIS,GILEAD ... $GILD, $IMGN, $SNY, $GSK, $INFY, $NVS,PCYC, $SGEN, $TGTX, ad a few more .. I will be following webcasts all weekend ...
-
Tricia: ...
I would argue that the big day is this weekend at $ASH, they are the "upstart" surprise from ASCO and are determined to get into the Cancer Arena. Recall their candidate Idelesibib trial was stopped by the FDA ... because the results $ARE SO PROMIS ... - Tricia: JUNO: put this name on your "tickler "to follow - the story is here - ... you can't buy it..... yet .... look at the collaborative names ... They will start 13 Phase 1 studies in 2014 alone ... Will be at $ASH next Week ...http://www.xconomy.com/seattle/2013/12/03/juno-therapeutics-grabs-120m-coax-immune-system-fight-cancer/?single_page=true IMMUNOTHERAPY for Cancer Treatment ... JUNO and another company Editas ... may IPO or be bought .... keeps the name on a post it...
- debeers: CELG/GILD-@DAN our beloved $CELG copped a neutral from Piper; @Tricia's $GILD caught an outperform with a 90 tag on its forehead. Just so you know, I trimmed $CELG and added to the $GILD going into the $ASH soon. I know I'm not the biotech Queen but you, on the other hand, Mr.Peeptoes....well. Have a happy Thanksgiving and thanks for making me $$.Since Bubba's best friends are dogs, love to yours as well.
-
Tricia: ...
-Detailed MM020 data at $ASH 2013 should clearly support CELG's view that Revlimid is best dosed until progression, and that lengthy Rev/dex dosing is not associated with increased risk of second primary malignancies (SPMs).
$CELG highlighted th ... - Tricia: GILD: CANCER UPDATE ... I told @DeBEERS the price target was 96.99 ..... she always underestimates - sigh .. 1. Gilead Sciences' Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 CLL ... http://bit.ly/1hRR4Z3 2. $GILD P3 #idelalisib #rituxan combo accepted as late $ASH abstract, http://bit.ly/1byunQM GILD: Gilead Sciences: European commission approves gilead's Vitekta, (HIV` therapy - an integrase inhibitor for the treatment of... http://bit.ly/1hRIWro GILD: FDA has granted idelalisib the coveted "Breakthrough Therapy designation" in relapsed #CLL based on Study 116 data, full data at ASH. It seems there are reports of CR's - that is right Complete Remissions - I am trying to confirm the $CR % and will pass on when i know ...
- Tricia: GILD: I have been reading for an hours ... can't sleep .. 10 Abstracts for $ASH .. Idelaisib ... it really is good news .. I think the data looks very strong ... There are two kinds of Investors ... those who are long $GILD :o) and those who wish they were .... :o( The heck with the charts ... I am buying more today for my nieces college fund ( it is a small account but she is a small kid lol)
-
Esslinger: $GILD - others may have posted already and I missed, if so my apologies. 10 abstracts selected at ASH!! See below! (CLL is particularly near and dear to my heart, I love to see the progress this company is making, horray!)
Gilead to Present Data o ... - Tricia: ASH: @otNAncy et all $ASH ABSTRACTS .the other day @otNancy generously posted a summary of companies who have a stake in the upcoming $ASH meeting. The registration is already at record It is expected to be a stellar 5 days of help and hope for many patients who suffer from blood cancer as well as blood component deficits - if you come across any abstracts this weekend would you post please .. and if you have oncology experience please comment ... Maybe we can get a separate area for $ASH abstracts, but for now just post thanks ..
- Tim S: Notable earnings before Tuesday's open $AFSI, $AKRX, $AMED, $AMG, $AOL, $ARCC, $ARCO, $ASH, $BCRX, $BDX, $BPI, $CCC, $CHTR, $COCO, $CTSH, $CVS, $D, $DLPH, $DNR, $DTV, $DWRE, $DX, $DXM, $EMR, $ENR, $EXH, EXLP, $EXPD, $FE, $GLDD, $GTIV, $HCA, $HCN, $HL, $HPT, $HSIC, $HST, $HW, $ICE, $IFF, $ISIS, $KORS, $KWK, $LBTYA, $LPX, $MITT, $MNTA, $MOS, $MPEL, $MPW, $NNN, $NTLS, $NXST, $ODP, $OMX, $OWW, OXF, $OZM, $PMC, $PQ, $RDC, $REGN, $REN, $RHP, $RIGL, $RRD, $RRGB, $SRE, $TGH, $TMUS, $TRGT, $TRP, $VSI, $XPO, $ZBRA, $ZINC, ZTS
- Tricia: CLDX: Rindopepimet study data it is possible e it leaked ... be aware that multiple Abstracts are showing up for AASLD, $ASH, ONc etc ... and I think embargo are being broken ..
- Tricia: $CELG : FANS ( I don not hold ... I belove the better opportunity is $GILD and a 2 year review and now even year to date confirms that - more catalysts and a much deeper pipeline that now includes Cancer ).... having said that ... The $ASH Abstracts are coming Thursday and Celgene's $MM 020 ... or Multiple Myeloma will be in this group .... everyone is very anxious for the $PFS --( progression free survival) ... keep that n mind ... knowing this kind of information can help your judgment. There will be abstract releases all week .. any of th Oncologists in SMM can help you .. I told you last weelkCelgene promised 3 blockbusters in Jan..... 2 down (1 busted, 2 a meh busters) and 1 to go ...keep a tight stop and if you are up .. bookem Dano ... bookem
-
Aragorn: ...
$BIDU AAPL $USU XLF $WFC BAC $WYNN LVS $ASH
How to Game the Opening Rotation - November 28, 2007
http://www.stockmarketmentor.com/public/712.cfm
@Golf77's 7-10 day theory
http://www.stockmarketmentor.com/members/forum/openthread.cfm?forum ... - Tricia: $CELG et All: Why did didn't Celg get a BIG BOOST form the good news of good trial data for psoriatic arthritis ??? after all - Apremilast will generate sales of $300 - $500M --- In January Management promised 1.1-7B ... what happened? Well , Abbbie's Humera and AMGN's Enbrel perform better and are cheaper in the whole rheumatoid group and Celgene thought they would become the new leaders ... but the data didn't back th em up and now the $'s don't. But the real concern is $ASH candidates and Myeloma .... I am still confirming but I do not believe Celene is in the leading candidate anymore ,,, poor management again I would not be holdin this into the pivotal meetings a.. $ASH for one ... There is a ton of info .. do some $DD and we can disucss or ... you can read your charts .
-
Tricia: ...
FD - 1/3 core position .. will wait till after $ASH ... but watching closely -
Tricia: ...
$NOV 6 - ABSTRACT for $ASH - Idelalisib (CELG and $PCYC are worried - they should be)
$ASH - Dec 7-10th - the data that stopped the trial because the results are so so promising - Idelasibid -
PDUFA - Dec 8 - $HEP C - $USA
This triu ... -
Tricia: ...
I have followed this company - even going to liver presentations and infectious disease presentations for the past 2 years ........ GILEAD is a superstar .... they own HIV, they will own HEPC and they have a candidate for CLL, MCL that they wil ... -
Tricia: ...
Therefore, one piece of data viewed as a negative or any problems with the FDA could send this stock crashing lower."
I have to agree with @Brian ..... I am only up 1000% since January 2012 when I started partitions in PCYC..... I think som ... - TD: $ASH - its going to 100 before november earnings - pull a weekly chart. $ROC confirming.
- TD: $ASH - no really - somebody wake me when it breaks 100 - for your weekly chart fans you really need to pull one. this is my last post on this. do not want to clutter the board needlessly.
-
DAN: ...
VAL: Specialty Chemical company. Makes coatings and paints for metal, wood, etc. Very thinly traded, which makes analyzing the chart a bit problematic just because one big buy or sell order can dramatically change the price. While it doesn't seem ... - Tricia: $PCYC - Another Upgrade ...... just another day in the life of the MMslayer .... ( multiple myeloma) $PCYC will make an $ASH of itself ( biotech joke) - the European Cancer conference is going on through the weekend .... but as I was advise ...
- Tricia: GERN: no position as I sold this last week.. .... this is up 23% on tweets saying ceo hinted promising myelofibrosis data - can $GERN reinvent itself? $ASH will tell but not until December -- this is bsically up on no data! ... use caution on this one --- I think it may be being manipulated .... if you have profits take them ...and enjoy ...
- TD: $ASH - challenge of the day - can anyone find a tighter WEEKLY #squeeze than this? this one was just over 6% in a weekly timeframe before it started to expand last week, the lowest state of volatility in over three years, now appears to just be getting started on an upside run, also has a high and rising 40 week average in close support - earnings in late October - but seriously, if anyone has identified a more coiled setup within the weekly timeframe it would be great to know.
- TD: $ASH - at 91.75 - volatility expansion day 3 on daily chart, but the story is in the weekly chart, tightest #squeeze in years, chemicals as a sector making the turn, just getting out of a super constructive #squeeze here. catalyst - earnings october 28 - test of 100? pull a weekly chart.
- TD: $ASH - the train appears ready to leave the station after a phase 2 intraday pullback - can anyone find a tighter #squeeze than this in a weekly timeframe?? this one is 9.8%. anyone??
- Tricia: ASTX@Woodman - I think there are other Leukemia drugs that are further along , but this was good news.... This year's $ASH ( Dec.) will be even bigger than ASCO .... it is an exciting hopeful time for blood cancer patients
- Tricia: GILD: up 5% premarket .... conference call ...4 Catalysts before year end .... the first of the 5 HCV treatment has AdComm Oct 25 and PDUFA Dec 8....the rest follow through out 2014 also they are filing 2 NDAs And $MAA for the Cancer drug Idlelisiib for mantle celL lymphoma - MCL, and for CLL Chronic Lymphocitic Leukemia and NHL Non-Hodkins Lymphoma .... incredible but if you recall, they were the Surprise star at ASCO ... $ASH is DEC. ....
- Tim S: Notable earnings before Thursday's open: $ABB, $ACT, $AEP, $AIXG, $ALK, $ALKS, $ARG, $ASH , $ASPS, $BC, $BG, $BIIB, $BLL, $BMS,BMY, $BSX, $BWA, $CAB, $CAM, $CCE, $CELG, $CFX , $CL, $CMS, $CNX, $COR, $CPN, $CRI,CRR, $CS, $CHS, @DAN, $DFT, $DHI, $DLX, $DNKN , $DO, $DOW, $DST, $EQT, $ESI, $FAF,FLIR, $GG, $GM, $GNC, $GPK, $GRA, $HNT, $HOG , $HOT, $HSY, $IDCC, $IMAX, IP, $JAH,JNS, $KEM, $KMT, $LAZ, $LL, $LM, LO, $LUV , $MDP, $MDSO, $MGI, $MHFI, $MJN, $MMM,NBL, $NMM, $NXTM, $ODFL, $ORI, $PACR, $PCP, $PDS , $PHM, $PNK, $POT, $PTEN, $QSII, $RCL,RDWR, $RS, $RTN, $RYN, $SIRI,SLAB, $STC, $STRA, $SUI, $TKR, $UA, $UFS, $USG , $UTHR, $VCI, $VDSI, $VLY, $WAB, $WCC,XRX, $YNDX, ZMH
-
Tricia: ...
On Thursday July 11, the stock made new highs on Revlimid data - but as the dust settled Friday # doubts arose again as there was no information on OS (overall survival) and there will not be until $ASH in Dec#
I don't know if it is the analy ...
| Stock Price | $95.99 |
| Change | 0.52% |
| Volume | 412,088 |
Ashland Inc. is a global specialty chemicals company that provides products, services and solutions that meet customer needs throughout a variety of industries.
Request Video of ASHAlready a member? Sign in here.
Past Month
Leading Peers
-
$56.24 21.79%
-
$22.23 2.87%
-
$24.09 2.31%
Past Month
Lagging Peers
-
$5.63 -34.38%
-
$8.65 -20.89%
-
$305.96 -12.65%
Dan Fitzpatrick
Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:
- Nightly video Strategy Sessions with a game plan for tomorrow
- Got a stock you want Dan to look at? Just ask.
- Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
- Access to over 90,400 stock analysis videos
- Access an ever expanding library (90,400) of educational videos that will save you time and make you money
Join a team of friends and traders that have one thing in common; a burning desire to succeed.
Become a Member Today!
Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...
Satisfaction Guaranteed!
Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!